JPWO2021239471A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021239471A5
JPWO2021239471A5 JP2022573287A JP2022573287A JPWO2021239471A5 JP WO2021239471 A5 JPWO2021239471 A5 JP WO2021239471A5 JP 2022573287 A JP2022573287 A JP 2022573287A JP 2022573287 A JP2022573287 A JP 2022573287A JP WO2021239471 A5 JPWO2021239471 A5 JP WO2021239471A5
Authority
JP
Japan
Prior art keywords
effective amount
weeks
construct
patient
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527083A (ja
JP2023527083A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/062728 external-priority patent/WO2021239471A1/en
Publication of JP2023527083A publication Critical patent/JP2023527083A/ja
Publication of JPWO2021239471A5 publication Critical patent/JPWO2021239471A5/ja
Publication of JP2023527083A5 publication Critical patent/JP2023527083A5/ja
Pending legal-status Critical Current

Links

Images

JP2022573287A 2020-05-29 2021-05-12 アレナウイルスベクターを使用するがんの治療方法 Pending JP2023527083A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063032362P 2020-05-29 2020-05-29
US63/032,362 2020-05-29
US202163173155P 2021-04-09 2021-04-09
US63/173,155 2021-04-09
US202163175842P 2021-04-16 2021-04-16
US63/175,842 2021-04-16
PCT/EP2021/062728 WO2021239471A1 (en) 2020-05-29 2021-05-12 Cancer treatment strategies using arenavirus vectors

Publications (3)

Publication Number Publication Date
JP2023527083A JP2023527083A (ja) 2023-06-26
JPWO2021239471A5 true JPWO2021239471A5 (https=) 2024-06-19
JP2023527083A5 JP2023527083A5 (https=) 2024-06-19

Family

ID=75914543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573287A Pending JP2023527083A (ja) 2020-05-29 2021-05-12 アレナウイルスベクターを使用するがんの治療方法

Country Status (12)

Country Link
US (1) US20230346906A1 (https=)
EP (1) EP4157342A1 (https=)
JP (1) JP2023527083A (https=)
KR (1) KR20230046278A (https=)
AU (1) AU2021282287A1 (https=)
BR (1) BR112022024404A2 (https=)
CA (1) CA3184791A1 (https=)
CR (1) CR20220602A (https=)
IL (1) IL298420A (https=)
MX (1) MX2022014725A (https=)
PE (1) PE20240647A1 (https=)
WO (1) WO2021239471A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
WO2023152116A1 (en) * 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3218504T (lt) 2014-11-13 2020-09-10 Université De Geneve Trijų segmentų arenavirusai kaip vakcinos vektoriai
EP3307308A2 (en) * 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
RS63546B1 (sr) 2015-11-12 2022-09-30 Hookipa Biotech Gmbh Čestice arenavirusa kao vakcine protiv kancera
US20190135875A1 (en) 2016-05-18 2019-05-09 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Similar Documents

Publication Publication Date Title
Lin et al. Oncolytic virotherapy: basic principles, recent advances and future directions
US11752206B2 (en) Herpes simplex virus vaccine
US20230022757A1 (en) Modified vaccinia vectors
Taguchi et al. Current status of clinical trials assessing oncolytic virus therapy for urological cancers
JP5963442B2 (ja) 免疫応答を誘発する天然痘ｄｎａワクチンおよびその中の抗原
CN108570455A (zh) 一种重组单纯疱疹病毒及其用途
CN105307671A (zh) 增强过继细胞疗法
WO2019080537A1 (zh) 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
CN108841796A (zh) 重组单纯疱疹病毒及其制备方法和应用
CN110305198A (zh) 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
CN111154806A (zh) 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
JP2026063215A5 (https=)
JP2023503858A (ja) ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用
JPWO2021239471A5 (https=)
Demidova et al. Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers
CN1110553C (zh) 基因工程腺病毒及其用途
EP3129037B1 (en) Poxviral oncolytic vectors
AU2020103637A4 (en) Recombinant oncolytic herpes simplex virus type ii and its pharmaceutical composition
US20220152168A1 (en) Sequential heterologous boost oncolytic viral immunotherapy
WO2024218165A1 (en) Hpv viral vector vaccine
CN119736337A (zh) Matv51重组腺病毒载体、应用、制备方法及hpv16/18/52治疗性疫苗
CN119101706A (zh) C2l基因缺失的溶瘤痘苗病毒载体的构建方法及应用
WO2025081515A1 (zh) 一种特异性标记异源蛋白的肿瘤新抗原疫苗体系及其应用
CN1517437B (zh) 特异性治疗肿瘤或胞内感染的疫苗及应用